CN111778014A - β-半乳糖苷酶近红外荧光探针及其制备方法和用途 - Google Patents
β-半乳糖苷酶近红外荧光探针及其制备方法和用途 Download PDFInfo
- Publication number
- CN111778014A CN111778014A CN201910275217.6A CN201910275217A CN111778014A CN 111778014 A CN111778014 A CN 111778014A CN 201910275217 A CN201910275217 A CN 201910275217A CN 111778014 A CN111778014 A CN 111778014A
- Authority
- CN
- China
- Prior art keywords
- beta
- galactosidase
- probe
- compound
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010005774 beta-Galactosidase Proteins 0.000 title claims abstract description 102
- 102000005936 beta-Galactosidase Human genes 0.000 title claims abstract description 100
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 65
- 238000001514 detection method Methods 0.000 claims abstract description 24
- 230000007246 mechanism Effects 0.000 claims abstract description 17
- 238000000799 fluorescence microscopy Methods 0.000 claims abstract description 6
- 238000003379 elimination reaction Methods 0.000 claims abstract description 5
- 239000000523 sample Substances 0.000 claims description 67
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 238000010898 silica gel chromatography Methods 0.000 claims description 13
- 238000012544 monitoring process Methods 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 7
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 7
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 6
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 6
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims description 6
- 239000012074 organic phase Substances 0.000 claims description 6
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 claims description 6
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910015900 BF3 Inorganic materials 0.000 claims description 3
- 229940126062 Compound A Drugs 0.000 claims description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003729 cation exchange resin Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 150000008195 galaktosides Chemical class 0.000 claims 1
- -1 beta-galactosyl Chemical group 0.000 abstract description 10
- 230000004044 response Effects 0.000 abstract description 7
- 238000003384 imaging method Methods 0.000 abstract description 6
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 230000007062 hydrolysis Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000005284 excitation Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 239000007853 buffer solution Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000000862 absorption spectrum Methods 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- 239000010453 quartz Substances 0.000 description 9
- 238000002189 fluorescence spectrum Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 230000005311 nuclear magnetism Effects 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000004847 absorption spectroscopy Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000001506 fluorescence spectroscopy Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910004879 Na2S2O5 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical compound C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910000144 sodium(I) superoxide Inorganic materials 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
- C09K2211/1055—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms with other heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属生物检测技术领域,涉及小分子荧光探针,具体涉及一类β‑半乳糖苷酶近红外荧光探针,尤其是氟硼二吡咯BODIPYβ‑半乳糖苷酶荧光探针及制备方法和在制备用于衰老细胞成像制剂中的用途。本发明的荧光探针可根据所述反应机制,即β‑半乳糖基水解、分子内自消除机理实现对β‑半乳糖苷酶的检测,且生物毒性较低,其光物理活性稳定,对β‑半乳糖苷酶响应的灵敏度高,可用于制备衰老细胞的特异性荧光成像的检测制剂。
Description
技术领域
本发明属生物检测技术领域,涉及小分子荧光探针,具体涉及一类β-半乳糖苷酶近红外荧光探针及制备方法和在制备用于衰老细胞成像制剂中的用途。
背景技术
现有技术公开了细胞衰老是指细胞在执行生命活动过程中,随着时间的推移,细胞增殖与分化能力和生理功能逐渐发生衰退的变化过程,细胞衰老是机体衰老和死亡的基础。研究显示,细胞衰老与多种老年性疾病如动脉粥样硬化、血管瘤、炎症疾病、肿瘤等有关。面临人口老化进程加快和人口寿命普遍提高的趋势,保障老年人享有良好的健康和较高的生活质量已成为社会科学和生命科学共同关注的重大问题,因此,开展衰老生物学和延缓衰老的研究具有重要的科学意义和社会价值,开发新的监测衰老细胞和生物体衰老状态的方法对医学诊断具有重要意义。
研究表明细胞在衰老状态下β-半乳糖苷酶出现过表达,因此,研究者认为β- 半乳糖苷酶可作为衡量细胞衰老状态的重要指标,对β-半乳糖苷酶的检测可在一定程度上反映生物体系的衰老状态。
荧光分析法具有高灵敏度、高选择性、高时空分辨率、操作简单并可实现对生物活性分子原位无损伤、实时快速的可视化成像等优点,已成为近年来的研究热点。目前,已有多种β-半乳糖苷酶荧光探针被陆续报道,但实践证实,现已存在的β-半乳糖苷酶探针仍然是水解反应后的电子推拉效应设计的,基于现有技术的现状,本申请的发明人拟提供新型反应机制的β-半乳糖苷酶探针及其制备方法和用途。
发明内容
基于现有技术的现状以及针对现有技术存在的问题,本发明的第一个目的是提供一类具有新型反应机制的β-半乳糖苷酶荧光探针,更具体的,涉及一种氟硼二吡咯(BODIPY)β-半乳糖苷酶荧光探针。
本发明第二个目的提供所述β-半乳糖苷酶荧光探针的制备方法。
本发明第三个目的提供所述荧光探针在制备对β-半乳糖苷酶实现高选择性和高灵敏度的检测制剂中的用途。
本发明的进一步目的是提供所述β-半乳糖苷酶荧光探针在制备用于衰老血管平滑肌细胞的荧光成像检测制剂中的用途。
本发明的目的通过下述技术方案实现:
本发明的基于新型反应机制的β-半乳糖苷酶荧光探针,其特征在于,β-半乳糖苷酶检测的识别基团为对-β-半乳糖基苄硫醚,其结构为:
所述得荧光基团为氟硼二吡咯类染料,其结构为:
本发明所述基于新型反应机制的β-半乳糖苷酶探针其结构为:
本发明所述β-半乳糖苷酶探针的合成路线为:
通过如下方法和步骤制备:
1)向化合物B的巯基乙酸溶液中加入三氟化硼乙醚溶液,室温反应,TLC 监测至反应结束,将溶液用乙酸乙酯稀释,用饱和食盐水洗,有机相经硅胶柱层析得黄色油状化合物C;
2)化合物C和α-D-五乙酰半乳糖的混合物用DMF溶解,加入三氟化硼乙醚溶液,室温反应,TLC监测至反应结束,将溶液用乙酸乙酯稀释,用饱和食盐水洗,有机相经硅胶柱层析得无水油状化合物D;
3)化合物D溶于甲醇,加入甲醇钠,TLC监测至反应结束,加入阳离子交换树脂调PH=7,过滤,浓缩得化合物白色固体E;
4)化合物E和化合物A溶于DMSO,加入三乙胺,室温反应,TLC监测至反应结束,经硅胶柱层析得化合物F;
5.化合物F溶于吡啶,加入三乙胺,分别和化合物G、H、I在80℃反应, TLC监测至反应结束,经硅胶柱层析得通式(1)探针。
本发明的实施例中按上述方法制得基于新型反应机制的β-半乳糖苷酶荧光探针,优选制得探针C-1,探针C-2,探针C-3,其中,
探针C-1结构为:
经检测,本发明的探针C-1的水溶性好,在PBS(10mM,pH7.4)缓冲溶液中,室温下可实现对β-半乳糖苷酶的检测识别,对β-半乳糖苷酶的响应速度快,反应时间30min,对β-半乳糖苷酶的响应为荧光增强型或比率型;其识别机理如下:
荧光探针分子中β-半乳糖基被酶水解,暴露出酚羟基,酚羟基发生分子内自消除,进一步生成荧光染料;
所述的β-半乳糖苷酶荧光探针C-1的特点为:可根据所述反应机制,即β- 半乳糖基水解、分子内自消除机理实现对β-半乳糖苷酶的检测,其反应前紫外最大吸收为488nm,激发波长为488nm,荧光最大发射为574nm,其反应后紫外最大吸收为651nm,激发波长为651nm,荧光最大发射为727nm,所述β-半乳糖苷酶荧光探针C-1本身可被激发出574nm的荧光,在37℃下,30%DMSO的 PBS缓冲液中,加入β-半乳糖苷酶后,574nm处的荧光降低为原来的60%,727 nm处荧光增强为原来的34.8倍;
所述β-半乳糖苷酶荧光探针C-1在各种分析物,如无机盐、氨基酸、氧化剂、还原剂、维生素、硫醇、其他生物活性酶存在下不受干扰,可实现对β-半乳糖苷酶的特异性检测;所述β-半乳糖苷酶探针C-1的生物毒性较低,可用于制备实现衰老细胞的特异性荧光成像的检测制剂。
探针C-2结构为:
经检测,本发明探针C-2的水溶性好,在PBS(10mM,pH7.4)缓冲溶液中,室温下可实现对β-半乳糖苷酶的检测识别,对β-半乳糖苷酶的响应速度快,反应时间60min,对β-半乳糖苷酶的响应为荧光增强型或比率型;
其识别机理如下:
荧光探针分子中β-半乳糖基被酶水解,暴露出酚羟基,酚羟基发生分子内自消除,进一步生成荧光染料;
本发明所述的β-半乳糖苷酶荧光探针C-2的特点为:
可根据所述反应机制,即β-半乳糖基水解、分子内自消除机理实现对β-半乳糖苷酶的检测;其反应前紫外最大吸收为535nm,激发波长为535nm,荧光最大发射为638nm,其反应后紫外最大吸收为670nm,激发波长为670nm,荧光最大发射为722nm;所述β-半乳糖苷酶荧光探针C-2本身可被激发出638nm 的荧光,在37℃下,30%DMSO的PBS缓冲液中,加入β-半乳糖苷酶后,638nm 处的荧光降低为原来的80%,722nm处荧光增强为原来的50.0倍;该β-半乳糖苷酶探针C-2的生物毒性较低,可用于制备实现衰老细胞的特异性荧光成像的检测制剂。
探针C-3结构为:
经检测,本发明的探针C-3的水溶性好,在PBS(10mM,pH7.4)缓冲溶液中,室温下可实现对β-半乳糖苷酶的检测识别,对β-半乳糖苷酶的响应速度快,反应时间20min,对β-半乳糖苷酶的响应为荧光增强型或比率型;
其识别机理如下:
荧光探针分子中β-半乳糖基被酶水解,暴露出酚羟基,酚羟基发生分子内自消除,进一步生成荧光染料;
本发明的β-半乳糖苷酶荧光探针C-3的特点为:
可根据所述反应机制,即β-半乳糖基水解、分子内自消除机理实现对β-半乳糖苷酶的检测,其反应前紫外最大吸收为533nm,激发波长为533nm,荧光最大发射为603nm,其反应后紫外最大吸收为721nm,激发波长为721nm,荧光最大发射为850nm,所述β-半乳糖苷酶荧光探针C-3本身可被激发出603nm 的荧光,在37℃下,30%DMSO的PBS缓冲液中,加入β-半乳糖苷酶后,603nm 处的荧光降低为原来的18%,850nm处荧光增强为原来的43.3倍;所述β-半乳糖苷酶探针C-3的生物毒性较低,可实现衰老细胞的特异性荧光成像检测。
本发明提供了氟硼二吡咯(BODIPY)β-半乳糖苷酶荧光探针及其制备方法和在用于制备衰老血管平滑肌细胞的荧光成像检测制剂中的用途,本发明的荧光探针光物理活性稳定,对β-半乳糖苷酶响应的灵敏度高。
附图说明
图1为探针C-1的核磁1H NMR图谱;
图2为探针C-1的核磁13C NMR图谱;
图3为探针C-1与β-半乳糖苷酶反应前后的紫外吸收光谱图;
图4为探针C-1与β-半乳糖苷酶前后的荧光发射光谱图;
图5为探针C-1与β-半乳糖苷酶反应的动力学实验图;
图6为探针C-1与不同浓度β-半乳糖苷酶反应的浓度滴定实验结果图;
图7为探针C-1与不同浓度β-半乳糖苷酶反应的浓度滴定实验结果图;
图8为探针C-1与β-半乳糖苷酶及各种干扰物质反应的选择性结果图;
图9为探针C-2的核磁1H NMR图谱;
图10为探针C-2的核磁13C NMR图谱;
图11为探针C-2与β-半乳糖苷酶反应前后的紫外吸收光谱图;
图12为探针C-2与β-半乳糖苷酶前后的荧光发射光谱图;
图13为探针C-2与β-半乳糖苷酶反应的动力学实验图;
图14为探针C-3的核磁1H NMR图谱;
图15为探针C-3的核磁13C NMR图谱;
图16为探针C-3与β-半乳糖苷酶反应前后的紫外吸收光谱图;
图17为探针C-3与β-半乳糖苷酶前后的荧光发射光谱图;
图18为探针C-3与β-半乳糖苷酶反应的动力学实验图;
图19为探针C-1衰老血管平滑肌细胞的荧光成像图。
具体实施方式
下面通过实施例和附图对本发明进行说明,但本发明的内容不受具体实施例的限制。
实施例1.
合成探针通式(1),其结构为:
探针的合成工艺为:
1)制备化合物C:
向化合物B(12g,96mmol)的巯基乙酸溶液(30mL)中加入三氟化硼乙醚溶液(1.8mL,13.2mmol),室温反应3h,TLC监测至反应结束。将溶液用乙酸乙酯稀释,用饱和食盐水洗,有机相经硅胶柱层析得黄色油状化合物C(14g,80%)。1H NMR(400MHz,CDCl3),δ2.27(s,3H),3.99(s,2H),5.66(s,1H),6.98(d,J=8.1Hz, 2H),7.07(d,J=8.1Hz,2H).ESI-MScalculated for C9H10NaO2S+[M+Na]+:205.03, found:205.1.
2)制备化合物D:
化合物C(11.7g,64mmol)和A-D-五乙酰半乳糖(12.5g,32mmol)的混合物用 DMF(100ml)溶解,加入三氟化硼乙醚溶液(10mL,64mmol),室温反应, TLC监测至反应结束。将溶液用乙酸乙酯稀释,用饱和食盐水洗,有机相经硅胶柱层析得无水油状化合物D(7.4g,45%)。1H NMR(600MHz,DMSO-d6)δ7.25 (d,J=8.6Hz,2H),6.92(d,J=8.6Hz,2H),5.42(d,J=7.9Hz,1H),5.33(d,J=3.5 Hz,1H),5.27(dd,J=10.4,3.5Hz,1H),5.19(dd,J=10.3,7.9Hz,1H),4.41(t,J= 6.4Hz,1H),4.09(dd,J=6.4,3.8Hz,2H),4.07(s,2H),2.34(s,3H),2.14(s,3H), 2.03(s,3H),2.00(s,3H),1.94(s,3H).13C NMR(151MHz,DMSO-d6)δ194.83, 169.97,169.83,169.55,169.21,155.55,132.29,130.01,116.47,97.78,70.30,70.13, 68.33,67.20,61.28,39.52,31.83,30.27,20.47,20.43,20.39,20.34.ESI-MScalculated for C23H28NaO11S+[M+Na]+:535.12,found:535.2.
3)制备化合物E:
化合物D(5.12g,10mmol)溶于甲醇100ml,加入甲醇钠3g,TLC监测至反应结束。加入阳离子交换树脂调PH=7,过滤,浓缩得化合物白色固体E(2.37g, 78.5%)。ESI-MScalculated for C13H18NaO6S+[M+Na]+:325.07,found:325.1.
4)制备化合物F:
化合物E(950mg,3.12mmol)和化合物A(400mg,1.04mmol)溶于DMSO 30 mL,加入三乙胺(145μl,1.04mmol),室温反应,TLC监测至反应结束,经硅胶柱层析得黄色固体化合物F(358mg,49.2%)。1H NMR(400MHz,CDCl3)δ8.94(s, 1H),7.39(m,3H),7.20(m,2H),6.83(d,J=8.1Hz,2H),6.76(d,J=8.1Hz,2H), 6.45(s,1H),4.73(m,1H),4.48(m,1H),4.38(m,1H),4.20(m,1H),4.00(m,2H), 3.62(m,2H),3.40(m,1H),2.67(s,3H),2.32(q,J=7.4Hz,2H),1.39(s,3H),0.97(t, J=7.4Hz,3H).ESI-MS calculated for C33H35BF2N2O7S[M+H]+:652.22,found: 652.3.
5)制备探针C-1:
化合物F(300mg,0.46mmol)和化合物G(92mg,1.38mmol)溶于吡啶,加入三乙胺(145μl,1.04mmol),80℃反应,TLC监测至反应结束,经硅胶柱层析得探针C-1(150mg,46.5%)。1H NMR(400MHz,DMSO-d6)δ7.65-7.41(m,6H),7.02 (d,J=8.3Hz,2H),6.92(d,J=8.0Hz,2H),6.81(s,1H),5.15(m,1H),4.91(m,1H), 4.76(m,1H),4.64(m,1H),4.53(m,1H),4.11(m,2H),3.52(m,4H),2.73(s,3H), 2.43(q,J=7.4Hz,2H),1.49(s,3H),1.01(s,J=7.4Hz,3H).12C NMR(151MHz, DMSO-d6),δ171.13,157.31,151.45,145.10,144.28,140.12,138.94,137.05,136.21, 131.95,130.27,130.15,129.92,129.68,128.85,128.80,127.10,118.92,116.46, 114.51,113.49,101.53,75.44,73.31,70.25,67.95,62.81,60.13,41.25,40.05,39.52, 16.57,14.05,13.61,12.37.HRMS(ESI,m/z):calculated forC36H35BF2N4NaO6S+ [M+Na]+:723.2231,found:723.2222.
5)制备探针C-2:
化合物F(300mg,0.46mmol)和化合物H(155mg,1.38mmol)溶于吡啶,加入三乙胺(145μl,1.04mmol),80℃反应,TLC监测至反应结束,经硅胶柱层析得探针C-2(130mg,38.1%)。1H NMR(400MHz,DMSO-d6)δ7.61(d,3H),7.49(d,2H), 7.12(s,1H),7.07(d,J=8.3Hz,2H),6.86(d,J=8.3Hz,2H),6.70(s,1H),5.16(d,J =5.0Hz,1H),4.88(d,J=5.0Hz,1H),4.66(d,2H),4.51(d,1H),4.17-4.09(m, 3H),3.68(s,1H),3.51(m,4H),3.16(d,2H),3.01(s,3H),2.67(s,3H),2.40(d,2H), 2.12(s,3H),1.44(s,3H),1.00(t,J=7.4Hz,3H).13C NMR(151MHz,DMSO-d6)δ 169.23,166.99,162.18,156.78,143.28,142.99,139.95,138.28,137.23,136.09, 134.62,132.84,129.94,129.44,128.92,128.74,124.49,116.55,116.17,101.05, 79.19,78.97,78.75,75.43,73.32,70.22,68.05,60.29,54.90,48.62,41.25,39.52, 26.19,16.53,15.40,13.83,13.61,12.17.ESI-MScalculated for C38H42BF2N4O7S+ [M+H]+:747.3,found:747.3.
5)制备探针C-3:
化合物F(300mg,0.46mmol)和化合物I(368mg,1.38mmol)溶于吡啶,加入三乙胺(145μl,1.04mmol),80℃反应,TLC监测至反应结束,经硅胶柱层析得探针C-2(104mg,25.1%)。1H NMR(400MHz,DMSO-d6)δ7.88(d,1H),7.80(m,2H), 7.65(m,3H),7.57(m,4H),7.25(d,1H),7.13(s,1H),7.01(d,J=8.0Hz,2H),6.85 (d,J=8.0Hz,2H),5.07(d,1H),4.87(s,1H),4.68(d,1H),4.58(s,1H),4.47(s,3H), 4.25(s,2H),3.63(s,1H),3.16(s,2H),2.74(s,3H),2.44(q,2H),1.52(s,3H),1.49(s, 3H),1.43(s,3H),1.31(q,3H),1.02(q,3H).13C NMR(151MHz,DMSO-d6)δ 180.85,169.86,156.80,145.99,144.93,144.04,143.17,140.33,139.78,139.55, 137.43,135.97,132.31,131.17,130.58,130.12,129.76,129.04,129.00,128.91, 128.83,122.94,120.62,116.18,114.64,109.96,100.61,75.30,73.22,70.11,67.87, 67.23,67.15,60.12,51.64,48.57,41.67,41.10,40.06,39.52,26.20,26.15,19.96, 16.52,13.89,13.63,13.52,12.14.ESI-MScalculated for C46H51BF2N3O6S+[M]+: 822.4,found:822.4.
实施例2 探针C-1与β-半乳糖苷酶反应前后的紫外吸收光谱图变化
配制30%DMSO的PBS溶液,现配现用;将探针配制成1mM的乙腈溶液,备用;将β-半乳糖苷酶(1mg,1580u/mg)用去离子水配制成1000u/mL的储备液,分装-20℃储存,备用,在3mL的石英比色皿中加入3mL 30%DMSO的PBS (pH 7.4,50mM)缓冲溶液,再依次加入10μL的探针,14μL的β-半乳糖苷酶, 37℃下反应30min,测量其吸收光谱,由图3看出,探针C-1在反应后,488nm 处的紫外最大吸收强度变弱,651nm处的紫外最大吸收强度变强。
实施例3.探针C-1与β-半乳糖苷酶反应前后的荧光发射光谱变化
在3mL的石英比色皿中加入3mL 30%DMSO的PBS(pH 7.4,50mM)缓冲溶液,再依次加入10μL的探针,14μL的β-半乳糖苷酶,37℃下反应30min,测量其吸收光谱,37℃下反应300min,测量其荧光发射光谱,激发波长488m,激发狭缝宽5nm,发射狭缝宽5nm,增益700V;激发波长651nm,激发狭缝宽 10nm,发射狭缝宽10nm,增益700V,图4显示了加入β-半乳糖苷酶后,574nm 处的荧光降低为原来的60%,727nm处荧光增强为原来的34.8倍。
实施例4.探针C-2与β-半乳糖苷酶反应前后的紫外吸收光谱图变化
配制30%DMSO的PBS溶液,现配现用;将探针配制成1mM的乙腈溶液,备用;将β-半乳糖苷酶(1mg,1580u/mg)用去离子水配制成1000u/mL的储备液,分装-20℃储存,备用,在3mL的石英比色皿中加入3mL 30%DMSO的PBS (pH 7.4,50mM)缓冲溶液,再依次加入10μL的探针,14μL的β-半乳糖苷酶, 37℃下反应30min,测量其吸收光谱,如图3所示,探针C-2在反应后,535nm 处的紫外最大吸收强度变弱,670nm处的紫外最大吸收强度变强。
实施例5 探针C-2与β-半乳糖苷酶反应前后的荧光发射光谱变化
在3mL的石英比色皿中加入3mL 30%DMSO的PBS(pH 7.4,50mM)缓冲溶液,再依次加入10μL的探针,14μL的β-半乳糖苷酶,37℃下反应30min,测量其吸收光谱,37℃下反应300min,测量其荧光发射光谱。激发波长535nm,激发狭缝宽5nm,发射狭缝宽5nm,增益700V;激发波长670nm,激发狭缝宽 10nm,发射狭缝宽10nm,增益700V,图4显示,加入β-半乳糖苷酶后,638nm 处的荧光降低为原来的80%,722nm处荧光增强为原来的50.0倍。
实施例6.探针C-3与β-半乳糖苷酶反应前后的紫外吸收光谱图变化
配制30%DMSO的PBS溶液,将探针配制成1mM的乙腈溶液,备用;将β-半乳糖苷酶(1mg,1580u/mg)用去离子水配制成1000u/mL的储备液,分装 -20℃储存,备用,在3mL的石英比色皿中加入3mL 30%DMSO的PBS(pH 7.4, 50mM)缓冲溶液,再依次加入10μL的探针,14μL的β-半乳糖苷酶,37℃下反应30min,测量其吸收光谱,图3显示,探针C-3在反应后,533nm处的紫外最大吸收强度变弱,721nm处的紫外最大吸收强度变强。
实施例7.探针C-3与β-半乳糖苷酶反应前后的荧光发射光谱变化
在3mL的石英比色皿中加入3mL 30%DMSO的PBS(pH 7.4,50mM)缓冲溶液,再依次加入10μL的探针,14μL的β-半乳糖苷酶。37℃下反应30min,测量其吸收光谱,37℃下反应300min,测量其荧光发射光谱。激发波长533nm,激发狭缝宽5nm,发射狭缝宽5nm,增益700V;激发波长721nm,激发狭缝宽 10nm,发射狭缝宽10nm,增益700V,图4显示,加入β-半乳糖苷酶后,603nm 处的荧光降低为原来的18%,850nm处荧光增强为原来的43.3倍。
实施例8.探针C-1(10μM)与β-半乳糖苷酶反应的动力学实验
在3mL的石英比色皿中加入3mL 30%DMSO的PBS(pH 7.4,50mM)缓冲溶液,再依次加入10μL的探针,14μL的β-半乳糖苷酶,激发波长651nm,激发狭缝宽10nm,发射狭缝宽10nm,增益700V,结果如图5所示,加入β- 半乳糖苷酶后5min后,检测到724nm处的荧光增强15.6倍,并且在前20min 内变化明显,之后随着时间的延长,荧光缓慢增强,反应30min后荧光强度趋于稳定,至此荧光信号增强了34.8倍,同时荧光最大发射波长也由574nm位移至727nm处。
实施例9.探针C-1(10μM)与β-半乳糖苷酶的浓度滴定实验
在3mL的石英比色皿中加入3mL 30%DMSO的PBS(pH 7.4,50mM)缓冲溶液,再依次加入10μL的探针,和各种浓度(0、0.5、1、2、4、6、8、10、 12、14u)的β-半乳糖苷酶,37℃下反应,300min,测量其荧光发射光谱。激发波长651nm,激发狭缝宽10nm,发射狭缝宽10nm,增益700V,图6显示,随着β-半乳糖苷酶浓度的增大,724nm处的荧光强度也不断增强,在0-8u的浓度范围内,荧光强度与β-半乳糖苷酶浓度呈良好的线性关系,线性方程为 Y=120.6X+51.18,R2=0.9954。
实施例10 探针C-1与各种干扰分析物反应的选择性实验
各分析物β-gal,cellulase,lysozyme,tripsin,NaHS,Cys,Hcy,GSH,DTT, NADH,Vitamin C,Na2S2O5,H2O2,NaClO均配制成3M的浓溶液,备用,在 3mL的石英比色皿中加入3mL30%DMSO的PBS(pH 7.4,50mM)缓冲溶液,再依次加入10μL的探针,14u的β-半乳糖苷酶或100equiv的各种分析物,37 ℃下反应30min,测量其荧光发射光谱,激发波长651nm,激发狭缝宽10nm,发射狭缝宽10nm,增益700V,图6显示,在其它分析物存在下探针C-1的荧光基本不发生改变,而加入β-半乳糖苷酶后荧光强度大幅度提升,表明探针C-1 可对β-半乳糖苷酶的检测不受其他物质干扰,可对β-半乳糖苷酶进行选择性检测。
实施例11.探针C-1检测衰老细胞成像图
将VSMCs细胞以3×105个/mL的浓度接种到35mm的共聚焦培养皿中,在 37℃,5%CO2的培养箱中孵育12小时后,将细胞分成两组,对照组在正常氧含量条件下继续培养72小时,实验组以Ang II诱导细胞衰老,培养72小时,随后分别加入10μM的探针C-1孵育1小时,吸掉培养液,并用PBS洗涤3次,加入无血清培养基,在荧光显微镜下观察,激发波长488nm,发射波段550-610 nm荧光为绿色通道;激发波长633nm,发射波段700-750nm荧光为绿色通道,结果如图8所示,正常培养的细胞有很强的绿色荧光,很弱的红色荧光,红色通道比绿色通道比值为0.4,而衰老的细胞,有很强的红色荧光,很弱的绿色荧光,红色通道比绿色通道比值为2;
进一步进行探针C-1、C-2、C-3细胞毒性实验,将VSMCs细胞以3×105个 /mL的浓度接种到96孔板中,在37℃,5%CO2的培养箱中孵育12小时后,再加不同浓度探针孵育24小时,随后每孔加CCK8溶液,1小时后用酶标仪读OD 值,结果显示,探针成像浓度均无明显细胞毒性,毒性不影响成像结果。
Claims (5)
2.根据权利要求1所述的β-半乳糖苷酶近红外荧光探针,其特征在于,其按如下合成路线和步骤制备:
(1)向化合物B的巯基乙酸溶液中加入三氟化硼乙醚溶液,室温反应,TLC监测至反应结束,将溶液用乙酸乙酯稀释,用饱和食盐水洗,有机相经硅胶柱层析得化合物C;
(2)化合物C和α-D-五乙酰半乳糖的混合物用DMF溶解,加入三氟化硼乙醚溶液,室温反应,TLC监测至反应结束,将溶液用乙酸乙酯稀释,用饱和食盐水洗,有机相经硅胶柱层析得化合物D;
(3)化合物D溶于甲醇,加入甲醇钠,TLC监测至反应结束,加入阳离子交换树脂调PH=7,过滤,浓缩得化合物E;
(4)化合物E和化合物A溶于DMSO,加入三乙胺,室温反应,TLC监测至反应结束,经硅胶柱层析得黄色固体化合物F;
(5)化合物F溶于吡啶,加入三乙胺,分别与化合物G、H、I在80℃反应,TLC监测至反应结束,经硅胶柱层析制得通式(1)探针。
5.根据权利要求1-4任一所述的β-半乳糖苷酶近红外荧光探针在制备用于检测衰老血管平滑肌细胞的荧光成像的制剂中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910275217.6A CN111778014B (zh) | 2019-04-04 | 2019-04-04 | β-半乳糖苷酶近红外荧光探针及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910275217.6A CN111778014B (zh) | 2019-04-04 | 2019-04-04 | β-半乳糖苷酶近红外荧光探针及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111778014A true CN111778014A (zh) | 2020-10-16 |
CN111778014B CN111778014B (zh) | 2024-01-02 |
Family
ID=72755165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910275217.6A Active CN111778014B (zh) | 2019-04-04 | 2019-04-04 | β-半乳糖苷酶近红外荧光探针及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111778014B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112505005A (zh) * | 2020-10-30 | 2021-03-16 | 南京医科大学 | 一种用于定量检测乳糖酶补充剂中β-Gal的比率型荧光探针的制备方法 |
CN113527389A (zh) * | 2021-07-27 | 2021-10-22 | 武汉工程大学 | 快速检测β-半乳糖苷酶的荧光探针及其制备方法和应用 |
CN114736255A (zh) * | 2022-05-11 | 2022-07-12 | 湖南超亟检测技术有限责任公司 | 检测β-半乳糖苷酶的黄酮衍生物荧光探针及其制备方法和应用、试剂盒及其使用方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106905389A (zh) * | 2017-01-24 | 2017-06-30 | 华东理工大学 | 一种具有细胞内滞留能力的β‑半乳糖苷酶荧光探针 |
CN108329366A (zh) * | 2018-03-07 | 2018-07-27 | 南京工业大学 | 一种用于检测β-半乳糖苷酶的荧光探针化合物及其制备方法 |
CN109134559A (zh) * | 2018-09-20 | 2019-01-04 | 济南大学 | 一种检测β-半乳糖苷酶的荧光探针及制备方法和应用 |
CN109180744A (zh) * | 2018-09-20 | 2019-01-11 | 济南大学 | 一种检测β-半乳糖苷酶的荧光探针 |
-
2019
- 2019-04-04 CN CN201910275217.6A patent/CN111778014B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106905389A (zh) * | 2017-01-24 | 2017-06-30 | 华东理工大学 | 一种具有细胞内滞留能力的β‑半乳糖苷酶荧光探针 |
CN108329366A (zh) * | 2018-03-07 | 2018-07-27 | 南京工业大学 | 一种用于检测β-半乳糖苷酶的荧光探针化合物及其制备方法 |
CN109134559A (zh) * | 2018-09-20 | 2019-01-04 | 济南大学 | 一种检测β-半乳糖苷酶的荧光探针及制备方法和应用 |
CN109180744A (zh) * | 2018-09-20 | 2019-01-11 | 济南大学 | 一种检测β-半乳糖苷酶的荧光探针 |
Non-Patent Citations (1)
Title |
---|
GE XU等: "Imaging of Colorectal Cancers Using Activatable Nanoprobe swith Second Near-Infrared Window Emission", 《ANGEW.CHEM.INT.ED.》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112505005A (zh) * | 2020-10-30 | 2021-03-16 | 南京医科大学 | 一种用于定量检测乳糖酶补充剂中β-Gal的比率型荧光探针的制备方法 |
CN113527389A (zh) * | 2021-07-27 | 2021-10-22 | 武汉工程大学 | 快速检测β-半乳糖苷酶的荧光探针及其制备方法和应用 |
CN113527389B (zh) * | 2021-07-27 | 2022-06-21 | 武汉工程大学 | 快速检测β-半乳糖苷酶的荧光探针及其制备方法和应用 |
CN114736255A (zh) * | 2022-05-11 | 2022-07-12 | 湖南超亟检测技术有限责任公司 | 检测β-半乳糖苷酶的黄酮衍生物荧光探针及其制备方法和应用、试剂盒及其使用方法 |
CN114736255B (zh) * | 2022-05-11 | 2023-10-27 | 湖南超亟检测技术有限责任公司 | 检测β-半乳糖苷酶的黄酮衍生物荧光探针及其制备方法和应用、试剂盒及其使用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111778014B (zh) | 2024-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gillian | Phosphinate-containing rhodol and fluorescein scaffolds for the development of bioprobes | |
Dong et al. | Two-photon red-emissive fluorescent probe for imaging nitroxyl (HNO) in living cells and tissues | |
CN111778014A (zh) | β-半乳糖苷酶近红外荧光探针及其制备方法和用途 | |
CN108844931B (zh) | Lzq荧光探针在同时检测so2衍生物和hsa中的应用 | |
Gong et al. | A novel two-photon fluorescent probe with long-wavelength emission for monitoring HClO in living cells and tissues | |
CN110357865B (zh) | 一种用于检测hNQO1酶的近红外荧光探针及其合成方法和应用 | |
CN109336815B (zh) | 一种检测细胞内质网内次氯酸的双光子荧光探针 | |
CN113999219B (zh) | 一种双位点荧光探针及其合成方法和应用 | |
CN106749034A (zh) | 对亚硫酸氢根和次氯酸根双响应比率型荧光标记试剂及其合成方法和应用 | |
CN111689938A (zh) | 一种高选择性次氯酸荧光探针的制备方法 | |
CN111285833A (zh) | 一种检测onoo-的比率型荧光分子探针及其制备方法和应用 | |
CN109928940B (zh) | 基于碱性蓝-3的检测次氯酸的近红外荧光探针分子的制备 | |
CN107286173B (zh) | Rhodol类衍生物及其制备方法和应用 | |
CN111073634B (zh) | 基于硝基还原、硫氮转位的硝基还原酶荧光探针及其制备方法 | |
CN112694471B (zh) | 一种苯并吲哚盐-吩噻嗪衍生物及其制备和应用 | |
CN109180716B (zh) | 一种多信号比率型区分检测h2o2和h2s的荧光探针的设计、合成及应用 | |
CN113637048B (zh) | 一种γ-谷氨酰转肽酶的双光子荧光探针及其制备方法和应用 | |
CN112500386A (zh) | 基于吡啰红肟的近红外HClO荧光探针、制备及其应用 | |
CN110655510B (zh) | 一种靶向脂滴的亚硫酸盐比率荧光探针及其应用 | |
CN109796966B (zh) | 一种次氯酸比率荧光探针及其应用 | |
CN109912581B (zh) | 基于香豆素与苯乙烯吡啶鎓的次氯酸荧光探针及其应用 | |
CN110483573B (zh) | 一种线粒体靶向次氯酸比率型双光子荧光探针及其制备方法和用途 | |
CN113788821B (zh) | 近红外联氨化合物、制备方法以及甲醛检测试剂盒和应用 | |
CN115594672A (zh) | 一种亚甲基蓝类近红外荧光探针及其制备方法和应用 | |
CN111362929B (zh) | 一种检测二氧化硫衍生物的比率荧光探针及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |